Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level

被引：3
|
作者：
Bazhenova, L. [1 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92037 USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷 / 04期
关键词：
1ST-LINE NIVOLUMAB; PLUS IPILIMUMAB; ADENOCARCINOMA; CHEMOTHERAPY; SENSITIVITY; ASSOCIATION; EFFICACY; OUTCOMES; NSCLC;
D O I：
10.1016/j.annonc.2023.02.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Loss of STK11 suppresses lipid metabolism to attenuate KRAS-induced immunogenicity in patients with non-small cell lung cancer
    Principe, Daniel
    Pasquinelli, Mary
    Nguyen, Ryan
    Feldman, Lawrence
    Aissa, Alexandre
    Weinberg, Frank D.
    CANCER RESEARCH, 2024, 84 (06)
  • [42] The association between STK11/LKB1 and/or KEAP1 mutations and response to PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer (NSCLC).
    Miller, Meagan Elizabeth
    Patel, Meera
    Althouse, Sandra K.
    Hanna, Nasser H.
    Mamdani, Hirva
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] KRAS G12 subtypes with co-mutated TP53, LRP1B, STK11, KEAP1 in lung cancer and their impact on TMB levels, PD-L1 expression and overall survival
    Zhao, Y.
    Wu, X.
    Tang, H.
    Qi, Q.
    Zhang, C.
    Liu, X.
    Huang, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1038 - S1039
  • [44] Association of NEDD9 Expression and Survival of Patients with KRAS Mutant and STK11 Mutant Non-Small Cell Lung Cancer (KRASMUT/STK11MUT-NSCLC)
    Judd, J.
    Gandhi, N.
    Xiu, J.
    Deneka, A.
    Khan, H.
    Karim, N. A.
    Liu, S. V.
    Naqash, A. R.
    Borghaei, H.
    Golemis, E.
    Hemenway, G.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S168 - S169
  • [45] The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas
    Mograbi, Baharia
    Heeke, Simon
    Hofman, Paul
    DIAGNOSTICS, 2021, 11 (02)
  • [46] STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort (vol 5, e000706, 2020)
    Papillon-Cavanagh, S.
    Doshi, P.
    Dobrin, R.
    ESMO OPEN, 2020, 5 (03)
  • [47] Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
    West, Howard Jack
    McCleland, Mark
    Cappuzzo, Federico
    Reck, Martin
    Mok, Tony Sk
    Jotte, Robert M.
    Nishio, Makoto
    Kim, Eugene
    Morris, Stefanie
    Zou, Wei
    Shames, David
    Das Thakur, Meghna
    Shankar, Geetha
    Socinski, Mark A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
  • [48] Identification of Immunotherapy Targets in STK11 Mutant Non-Squamous Non-Small Cell Lung Cancer
    Yau, E.
    Glenn, S.
    Papinicalou-Sengos, A.
    Nesline, M.
    Morrison, C.
    Dy, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S442 - S442
  • [49] Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.
    Ricciuti, Biagio
    Arbour, Kathryn Cecilia
    Lin, Jessica Jiyeong
    Vokes, Natalie
    Hoojghan, Amir Vajdi
    Li, Yvonne Y.
    Cherniack, Andrew D.
    Recondo, Gonzalo
    Lamberti, Giuseppe
    Venkatraman, Deepti
    Rizvi, Hira
    Egger, Jacklynn, V
    Plodkowski, Andrew J.
    Khosrowjerdi, Sara
    Digumarthy, Subba R.
    Nishino, Mizuki
    Sholl, Lynette M.
    Gainor, Justin F.
    Hellmann, Matthew David
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] STK11 and KEAP1 mutational status and their impact in survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: Meta-analyses of clinical trials and cohort studies
    de Castro, G., Jr.
    Kashiura, D.
    Harada, G.
    Lima Torres, L.
    Codima, A.
    Monteiro, G.
    Costa, I. G.
    Julian, G. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S848 - S848
12345